Sort
82,697 grants matching “vaccine development”
Treatment of Inflammatory Complications of Respiratory Infection
$1,000,000Michael William Lark · Respana Therapeutics, Inc. · R42 · FY2024 · AI
SIRPant Technology for anti-Cancer Immunity
$1,000,000Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2023 · CA
Experimental Gonococcal Vaccine
$1,000,000Dominick Auci · Therapyx, Inc. · R44 · FY2022 · AI
Development of an E6 based Rapid Strip Test Commercial Prototype for Cervical Can
$1,000,000Johannes G Schweizer · Arbor Vita Corporation · R44 · FY2010 · AI
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle
$1,000,000Mark E McDonnell · Fox Chase Chemical Diversity Center, Inc · R44 · FY2024 · AI
Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.
$1,000,000Nhi Khuong · Lumen Bioscience, Inc. · R42 · FY2021 · AI
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES
$1,000,000Tyson Heilherker · Boston Children'S Hospital · N01 · FY2025 · AI
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products
$1,000,000Peter F. Billingsley · Sanaria, Inc. · R44 · FY2023 · AI
DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2021 · AI
Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe
$1,000,000Wu-Bo Li · Functional Genetics, Inc. · R44 · FY2011 · AI
Respiratory Virus Vaccine and Adjuvant Exploration
$1,000,000Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2023 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2014 · AI
University of New Mexico Cancer Center Support Grant
$1,000,000Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2020 · CA
A Vaccine for Lymphatic Filariasis, LFGuardâ¢
$1,000,000Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2021 · AI
Development of VLP vaccine for RSV
$1,000,000Jorge C Blanco · Sigmovir Biosystems, Inc. · R44 · FY2020 · AI
IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2014 · AI
Novel Therapy for Pulmonary Anthrax
$1,000,000Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2011 · AI
An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC
$1,000,000Jennifer A Schwartz · Profectus Biosciences, Inc. · R44 · FY2016 · AI
Improving Absorption and Targeting of Antiviral Drugs
$1,000,000John M Hilfinger · Tsrl, Inc. · R44 · FY2009 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
$1,000,000Michael David Alpert · Emmune, Inc · R44 · FY2024 · AI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model
$1,000,000Marc Joseph Gurwith · Paxvax, Inc. · R44 · FY2013 · AI
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2020 · AI
Improving Absorption and Targeting of Antiviral Drugs
$1,000,000John M Hilfinger · Tsrl, Inc. · R44 · FY2007 · AI
Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
$1,000,000Sumana Chakravarty · Sanaria, Inc. · U44 · FY2025 · AI
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques
$1,000,000Yvonne J Rosenberg · Plantvax, Inc. · R44 · FY2016 · AI